Publications by authors named "Nathaniel D Catron"

Claim this Profile
P
Pharmaceutical Development Challenges in a Beyond Rule of Five Prodrug: Case Study of ABBV-167, Phosphate Prodrug of Venetoclax.
Richard Hong, Haichen Nie, Rodger F Henry, Sean M Garner, Nathaniel D Catron

Mol Pharm· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers.
Ahmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, Jie Chen, Shuang Chen, Nathaniel D Catron

Mol Cancer Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X Inhibitor.
Le Wang, George A Doherty, Andrew S Judd, Zhi-Fu Tao, T Matthew Hansen, Nathaniel D Catron

ACS Med Chem Lett· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Modeling of Micellar Solubilization by Single and Mixed Nonionic Surfactants.
Shaoxin Feng, Nathaniel D Catron, Alan Donghua Zhu, John M Lipari, Jianwei Wu

J Pharm Sci· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody-Drug Conjugate Aggregation and Drug Release.
Kenneth R Durbin, M Shannon Nottoli, Nathaniel D Catron, Nicole Richwine, Gary J Jenkins

ACS Omega· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Solubilizing Additives on Supersaturation and Membrane Transport of Drugs.
Shweta A Raina, Geoff G Z Zhang, David E Alonzo, Jianwei Wu, Donghua Zhu, Nathaniel D Catron

Pharm Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.
Zhi-Fu Tao, Lisa Hasvold, Le Wang, Xilu Wang, Andrew M Petros, Nathaniel D Catron

ACS Med Chem Lett· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs.
Shweta A Raina, Geoff G Z Zhang, David E Alonzo, Jianwei Wu, Donghua Zhu, Nathaniel D Catron

J Pharm Sci· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.
Edna F Choo, Jason Boggs, Chunqiang Zhu, Joseph W Lubach, Nathaniel D Catron

Drug Metab Dispos· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron

Nat Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of poly(ethylene glycol) mucoadsorption by biomimetic end group functionalization.
Nathaniel D Catron, Haeshin Lee, Phillip B Messersmith

Biointerphases· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis